Abstract
Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups. The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences across regimens, can be broadly classified as including induction, consolidation, maintenance, and central nervous system prophylaxis. Although there has been marked improvement in the outcomes for pediatric patients with ALL, the same success has not yet been realized for adult patients. Some of this difference can be attributed to a greater incidence of unfavorable cytogenetic subtypes in adults than in children. In addition, the ability to tolerate intensive regimens likely plays a role. This article reviews the classification, prognostic features, current treatment programs, and new advances as applied to adult patients with newly diagnosed ALL.
Similar content being viewed by others
References and Recommended Reading
Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.
Lamanna N, Weiss M: Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep 2004, 3:40–46.
Hoelzer D, Gokbuget N, Ottmann O, et al.: Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002, 162–192.
Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535–1548.
Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664–674.
Thomas DA, Cortes J, O’Brien S et al.: Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461–2470.
Lee EJ, Petroni GR, Schiffer CA et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014–4022.
Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.
Scandura JM: Advances in the molecular genetics of acute leukemia. Curr Oncol Rep 2005, 7:323–332.
Sutcliffe MJ, Shuster JJ, Sather HN, et al.: High concordance from independent studies by the Children’s Cancer Group (CCG) and Pediatric Oncolog y Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children’s Oncolog y Group (COG) initiative. Leukemia 2005, 19:734–740.
Groupe Français de Cytog’en’etique H’ematologique:Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Group Français de Cytog’en’etique H’ematologique. Blood 1996, 87:3135–3142.This paper demonstrates karyotypic differences between adult and childhood ALL and the prognostic implications of karyotypes.
World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.
Hecht JL, Aster JC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol 2000, 18:3707–3721.
Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269–271.This article reports common activating mutations of NOTCH1 and presents a rationale for a new clinical strateg y for the treatment of T-cell ALL.
Arico M, Valsecchi MG, Camitta B, et al.: Outcome of treatment in children with Philadelphia chromosome -positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998–1006.
Chessells JM, Hall E, Prentice HG, et al.: The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998, 12:463–473.
Ohno R: Current progress in the treatment of adult acute leukemia in Japan. Jpn J Clin Oncol 1993, 23:85–97.
Weiss MA, Heffner L, Lamanna N, et al., for the ALL-4 Consortium: A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL [abstract]. J Clin Oncol (Meeting Abstracts) 2005, 23:6516.
Gaynor J, Chapman D, Little C, et al.: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988, 6:1014–1030.One of two "classic" papers on prognostic factors in adult ALL.
Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123–131. One of two "classic" papers on prognostic factors in adult ALL.
Boucheix C, David B, Sebban C et al.: Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994, 84:1603–1612.
Den Boer ML, Harms DO, Pieters R, et al.: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21:3262–3268.
Schauer P, Arlin ZA, Mertelsmann R, et al.: Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983, 1:462–470. The first major paper to demonstrate that adult ALL is a curable neoplasm.
Hoelzer D, Thiel E, Loffler H, et al.: Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984, 64:38–47.
Kantarjian HM, O’Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547–561.
Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464–2471.
Larson R A, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025–2037.
Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811–1822.
Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term followup of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863–871.
Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259–1266.
Gottlieb AJ, Weinberg V, Ellison RR, et al.: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984, 64:267–274.
Weiss M, Maslak P, Feldman E, et al.: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14:2480–2485.This article shows the efficacy of a novel approach to ALL induction therapy with high-dose mitoxantrone and cytarabine. This study led to the recently completed randomized phase III clinical trial comparing the novel regimen to a standard induction program.
Fiere D, Extra JM, David B, et al.: Treatment of 218 adult acute lymphoblastic leukemias. Semin Oncol 1987, 14:64–66.
Toyoda Y, Manabe A, Tsuchida M, et al.: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000, 18:1508–1516.
Schrappe M, Reiter A, Zimmermann M, et al.: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000, 14:2205–2222.
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 1996, 347:1783–1788.
Cassileth PA, Andersen JW, Bennett JM, et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncolog y Group experience. Leukemia 1992, 6(Suppl 2):178–181.
Cuttner J, Mick R, Budman DR, et al.: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 1991, 5:425–431.
Dekker AW, van’t Veer MB, Sizoo W, et al.: Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 1997, 15:476–482.
Scheinberg DA, Maslak PG, Weiss MA: Acute leukemias. In Cancer: Principles and Practice of Oncology, edn 7. Edited by DeVita V T Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2005:2088–2116.
Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784–1789.
Omura GA, Moffitt S, Vogler WR, Salter MM: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980, 55:199–204.
Burger B, Zimmermann M, Mann G, et al.: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003, 21:184–188.
Sebban C, Lepage E, Vernant JP, et al.: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994, 12:2580–2587.The randomized trial showed no benefit for allogeneic or autologous transplantation in first complete remission for adults with ALL.
Zhang MJ, Hoelzer D, Horowitz MM, et al.: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med 1995, 123:428–431.
Dombret H, Gabert J, Boiron JM et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357–2366. The best evidence to date that allogeneic transplantation improves the outcome for patients with Ph+ and high-risk ALL.
Kiehl MG, Kraut L, Schwerdtfeger R, et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816–2825.This study found similar outcomes for patients who received matched related or unrelated allografts, potentially increasing thetransplantation options for high-risk patients.
Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276–2285.
Laughlin MJ, Eapen M, Rubinstein P, et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265–2275.
Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251–5256.
Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094–1104.
Vidriales MB, Perez JJ, Lopez-Berges MC, et al.: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695–4700.
Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116–1123.Although this study highlights the limitations of minimal residual disease (MRD) evaluation, it demonstrates that MRD can be an important prognostic tool in adults with ALL.
Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.
Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.Although the effects of imatinib are less dramatic in Ph+ ALL than in CML, the combination of imatinib and chemotherapy appears to have important clinical benefit for these patients.
Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.
Lee KH, Lee JH, Choi SJ, et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509–1516.
Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084–1089.
Boissel N, Auclerc MF, Lheritier V, et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774–780.This provocative paper is the first of four recent studies indicating that young adults benefit from treatment with more aggressive "pediatric-style" regimens.
de Bont JM, Holt B, Dekker AW, et al.: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004, 18:2032–2035.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Landau, H., Lamanna, N. Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep 1, 171–179 (2006). https://doi.org/10.1007/s11899-996-0005-8
Issue Date:
DOI: https://doi.org/10.1007/s11899-996-0005-8